Overcoming MCL-1-driven adaptive resistance to targeted therapies
Kris C. Wood
Abstract
Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clinic.
Topics & Concepts
Cancer researchAdaptive responseAcquired resistanceMedicineOncogeneDrug resistanceApoptosisBiologyBioinformaticsComputational biologyGeneticsCell cycleCell death mechanisms and regulationPhagocytosis and Immune RegulationCancer Mechanisms and Therapy